Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort

被引:96
|
作者
Sieri, Sabina [1 ]
Krogh, Vittorio [1 ]
Bolelli, Gianfranco [7 ]
Abagnato, Carlo Alberto [7 ]
Grioni, Sara [1 ]
Pala, Valeria [1 ]
Evangelista, Alberto [1 ]
Allemani, Claudia [2 ]
Micheli, Andrea [3 ]
Tagliabue, Giovanna [4 ]
Schunemann, Holger J. [8 ]
Menard, Sylvie [5 ]
Berrino, Franco [6 ]
Muti, Paola [8 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Nutr Epidemiol Unit, I-20133 Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Analyt Epidemiol Unit, I-20133 Milan, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Descript Epidemiol & Hlth Planning Unit, I-20133 Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Canc Registry Div, I-20133 Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Labs & Dept Expt Oncol, Mol Biol Unit, I-20133 Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Etiol & Prevent Epidemiol Unit, I-20133 Milan, Italy
[7] Ctr Med Diagnost Emilia, Bologna, Italy
[8] Ist Regina Elena, Epidemiol & Prevent Unit, I-00161 Rome, Italy
关键词
METABOLIC-SYNDROME; ESTROGEN-RECEPTOR; GENE-EXPRESSION; ENDOGENOUS ESTROGENS; PROGESTERONE; ANDROGEN; TESTOSTERONE; CARCINOMAS; GROWTH;
D O I
10.1158/1055-9965.EPI-08-0808
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Endogenous sex hormone levels have been associated with increased breast cancer risk in postmenopausal women in several prospective studies. However, it remains unclear to what extent serum hormone-breast cancer associations differ with receptor status. Methods: Associations between serum sex hormone levels and breast cancer risk were assessed in a nested case-control study on postmenopausal women of the ORDET cohort. After a median follow-up of 13.5 years, 1.65 women developed breast cancer. Relative risks of developing breast cancer were estimated by conditional logistic regression. Results: Total and free testosterone levels were directly associated with breast cancer risk [relative risk, 3.28 (95% confidence interval, 1.93-5.55) and 2.86 (95% confidence interval, 1.66-4.94), respectively, for highest versus lowest quartile]. When relations between hormone level and risk of breast cancer expressing various receptor combinations were assessed, high total testosterone was significantly associated with increased risk of estrogen receptor-positive cancers, irrespective of progesterone receptor status. High total testosterone was also associated with increased risk of both human epidermal growth factor receptor 2 (HER2)-negative (HER2(-)) and HER2(+) cancers. High estradiol tended to be associated with increased risk of HER2- cancer and inversely associated with HER2(+) cancer, with significant (P = 0.027) heterogeneity between HER2(+) and HER2- cancers. However, there were relatively few HER2(+) cases. Conclusions: This study provides further evidence that high levels of circulating testosterone increase the risk of developing breast cancer in postmenopausal women. The cancers that develop are mainly estrogen receptor positive. Although HER2(+) and HER2- breast cancers were both associated with high total testosterone, they showed opposing associations with estrogen. (Cancer Epidemiol Biomarkers Prev 2009;18(1):169-76)
引用
收藏
页码:169 / 176
页数:8
相关论文
共 50 条
  • [1] Serum sex hormone levels and hormone receptor status in identifying breast cancer risk in women
    Akalanka, Kasuni H. M.
    Ekanayake, Sagarika
    Samarasinghe, Kamani
    INDIAN JOURNAL OF CANCER, 2021, 58 (04) : 525 - 531
  • [2] Predicting risk of breast cancer in postmenopausal women by hormone receptor status
    Chlebowski, Rowan T.
    Anderson, Garnet L.
    Lane, Dorothy S.
    Aragaki, Aaron K.
    Rohan, Thomas
    Yasmeen, Shagufta
    Sarto, Gloria
    Rosenberg, Carol A.
    Hubbell, F. Allan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (22): : 1695 - 1705
  • [3] Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort
    Schernhammer, Eva S.
    Sperati, Francesca
    Razavi, Pedram
    Agnoli, Claudia
    Sieri, Sabina
    Berrino, Franco
    Krogh, Vittorio
    Abbagnato, Carlo Alberto
    Grioni, Sara
    Blandino, Giovanni
    Schunemann, Holger J.
    Muti, Paola
    BREAST CANCER RESEARCH, 2013, 15 (03)
  • [4] Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
    Dorgan, JF
    Longcope, C
    Stanczyk, FZ
    Stephenson, HE
    Hoover, RN
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (04) : 380 - 381
  • [5] Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
    Hankinson, SE
    Willett, WC
    Manson, JE
    Colditz, GA
    Hunter, DJ
    Spiegelman, D
    Barbieri, RL
    Speizer, FE
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (17): : 1292 - 1299
  • [7] Serum sex hormone levels are related to breast cancer risk in postmenopausal women
    Dorgan, JF
    Longcope, C
    Stephenson, HE
    Falk, RT
    Miller, R
    Franz, C
    Kahle, L
    Campbell, WS
    Tangrea, JA
    Schatzkin, A
    ENVIRONMENTAL HEALTH PERSPECTIVES, 1997, 105 : 583 - 585
  • [8] Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.
    Hankinson, SE
    Willett, WC
    Manson, JE
    Colditz, GA
    Hunter, DJ
    Spiegelman, D
    Barbieri, RL
    Speizer, FE
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (11) : S89 - S89
  • [9] Alcohol and Risk of Breast Cancer by Histologic Type and Hormone Receptor Status in Postmenopausal Women
    Lew, Jasmine Q.
    Freedman, Neal D.
    Leitzmann, Michael F.
    Brinton, Louise A.
    Hoover, Robert N.
    Hollenbeck, Albert R.
    Schatzkin, Arthur
    Park, Yikyung
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 170 (03) : 308 - 317
  • [10] Urinary 6-Sulphatoxymelatonin Levels and Risk of Breast Cancer in Premenopausal Women: The ORDET Cohort
    Schernhammer, Eva S.
    Berrino, Franco
    Krogh, Vittorio
    Secreto, Giorgio
    Micheli, Andrea
    Venturelli, Elisabetta
    Grioni, Sara
    Sempos, Christopher T.
    Cavalleri, Adalberto
    Schuenemann, Holger J.
    Strano, Sabrina
    Muti, Paola
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (03) : 729 - 737